Purdue Pharma has reportedly settled a consolidated federal lawsuit made up of more than 2,000 cities and counties accusing the OxyContin maker of being responsible for the country’s sweeping opioid crisis
.
States across the country have launched legal action against opioid manufacturers. Nevada, Idaho, California, Hawaii, Maine and the District of Columbia all filed lawsuits against Purdue Pharma in June. In fact, every state except Nebraska has sued, filed administrative charges or promised to sue companies accused of being responsible for the opioid crisis, The Associated Press reported.
The CDC says that opioid overdoses killed more than 47,000 people in 2017, 35% of which involved prescription opioids such as OxyContin. That is six times higher than the opioid deaths in 1999, the same decade Purdue Pharma created OxyContin, an addictive painkiller.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Purdue Pharma Close to Settlement with Cities and Half of States Over Opioid CrisisPurdue Pharma is close to securing support from states and local governments for a multibillion-dollar deal that will enable it to resolve mounting litigation.
Consulte Mais informação »
The Sackler family could give up Purdue Pharma, source saysThe Sackler family could give up its ownership of Purdue Pharma and up to $4.5 billion of their own money, as one possible settlement option over the more than 2,000 lawsuits filed against their company, a person with knowledge of the negotiations tells CNN.
Consulte Mais informação »
Exclusive: Purdue Pharma nears partial opioid settlement, bankruptcy filing - sourcesOxyContin maker Purdue Pharma LP is nearing a partial agreement to resolve wides...
Consulte Mais informação »
Opioid talks break down; Purdue owners balk at paying $4.5 billionSettlement talks between Purdue Pharma and the states and cities suing the opioid maker stall after state officials ask for $4.5B instead of a discussed guarantee of $3B
Consulte Mais informação »
Pharma stocks fall as draft of House Democratic drug price plan surfaces on Capitol HillThe main thrust of the plan, which is still in flux, would allow Medicare to negotiate lower prices on the 250 most expensive drugs and apply those discounts to private health plans across the U.S.
Consulte Mais informação »